All TP53 mutations are NOT equal: Does the "deleterious effect" of the TP53 mutation affect the outcome of Myelodysplastic Syndrome?
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Recommendations from the European Commission Initiative on Breast Cancer (ECIBC) for multigene testing
In the EU, including UK, 404,920 women were diagnosed with breast cancer (BC) and 98,755 died in 2018 (ECIS 2018). As BC outcomes differ across Europe, the ECIBC aimed to develop adaptable recommendations on BC prevention and diagnosis and a quality assurance scheme applicable throughout Europe.
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
Unveiling mechanisms of resistance to immunotherapy: Tumor intrinsic JAK2 downmodulation leads to IFN-gamma deficient response and acquired resistance to T cell redirection therapies